3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
2
Genitourinary
2
Tumor-Agnostic
1
Sarcoma
1
Plasma cell
1
Head & Neck
1
Gastrointestinal
1
Dermatologic
1
Conditions
Vomiting
1
Melanoma
1
Carcinoma, Renal Cell
1
Interventions
Ipilimumab
101
pembrolizumab
94
Nivolumab
87
Cyclophosphamide
69
fludarabine phosphate
55
aldesleukin
52
Interleukin-2
39
Dacarbazine
35
Vemurafenib
31
fludarabine
30
trametinib
29
dabrafenib
29
Temozolomide
28
Whole-Body Irradiation
21
Aminolevulinic Acid
21
Carboplatin
20
CTLA-4 Antigen
20
Bevacizumab
20
Radiotherapy
19
Peripheral Blood Stem Cell Transplantation
19
Radiosurgery
18
Tacrolimus
17
Mycophenolic Acid
17
Paclitaxel
16
HhAntag691
16
3-ingenyl angelate
16
Busulfan
15
Introns
14
Antilymphocyte Serum
14
encorafenib
13
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
fosaprepitant
×
Dermatologic
×
Clear all
NCT01874119
2018-06-07
HDIL2/Emend
St. Louis University
Phase 2
Terminated
13 enrolled
7 charts